CCR6 and prostate cancer: Gene regulatory networks in the RM1 bone metastasis microenvironment involved NFKB1, STAT1, IRF8, and JUN family proteins, emphasizing their roles in immune suppression and tumor progression.<h4>Conclusions</h4>These results suggest that targeting CCR6 may enhance immunotherapy efficacy in prostate cancer bone metastasis by reshaping the immune microenvironment.